Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Stifel raised its price target on Celcuity Inc (NASDAQ:CELC) to $68.00 from $65.00 on Friday, while maintaining a Buy rating on the stock. The company’s shares, currently trading at $52.06, have surged 13.1% in the past week and an impressive 296% year-to-date, according to InvestingPro data.
The research firm cited Celcuity’s reiteration of the VIKTORIA-1 top-line results and the company’s plans to present primary analysis and full safety data at a medical congress by year-end, excluding exploratory and subgroup analyses. The market has responded positively to these developments, with analyst consensus being highly bullish and price targets ranging from $45 to $79.
Stifel noted management’s confidence in gedatolisib’s broad eligibility regardless of metabolic fitness and PIK3CA mutation status, with expectations that a statistical win in PIK3CA-mutated patients would be clinically meaningful by potentially adding three months to the approximately 7-8 months of median progression-free survival seen with alpelisib.
The firm highlighted gedatolisib plus fulvestrant doublet’s potential as a standard of care for PIK3CA wild-type patients, which Stifel called a "timely message" given Arvinas’s apparent reluctance to launch vepdegestrant monotherapy without a partner to replace Pfizer.
Celcuity’s first New Drug Application submission for the wild-type indication and the second top-line results for PIK3CA-mutated patients are expected in the fourth quarter of 2025, according to the report. InvestingPro analysis shows the company maintains a FAIR financial health score, with 15+ additional insights available to subscribers through detailed Pro Research Reports.
In other recent news, Celcuity reported its second-quarter 2025 financial results, revealing a loss of $1.04 per share, which fell short of analysts’ expectations of a $0.88 loss. This earnings miss resulted in an 18.18% negative surprise. Despite this, Jefferies raised its price target for Celcuity to $79.00, citing "unprecedented" progression-free survival data from a Phase III study in second-line PIK3CA wild-type HR+/HER2- advanced breast cancer. Conversely, Needham adjusted its price target for Celcuity to $70.00 from $74.00 due to concerns about dilution following the earnings release. Both Jefferies and Needham maintained a Buy rating on the stock. These developments reflect a mixed sentiment among analysts, with positive trial data being a notable highlight. Investors are closely monitoring these updates as they assess Celcuity’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.